Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Hutchmed heats up autoimmune race with phase 3 win
The phase 3 trial hit its primary endpoint, delivering a boost to an asset that was held up by quality issues in another indication.
Nick Paul Taylor
Jan 7, 2026 4:39am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Nektar claims ph. 2 alopecia success after excluding 4 patients
Dec 16, 2025 5:05pm
Pfizer, Sanofi round out '25 with separate autoimmune deals
Dec 15, 2025 11:06am
Sanofi, GSK ink preclinical pacts in hunt for new antibodies
Dec 10, 2025 11:15am
Formation Bio makes $605M play for Lynk's TYK2 inhibitor
Dec 10, 2025 10:27am